CoChat

Modulation of human embryonic stem cell-derived cardiomyocyte growth: A testbed for studying human cardiac hypertrophy?

Open access
Földes, Gábor, Mioulane, Maxime, Wright, Jamie S., Liu, Alexander Q., Novak, Pavel, Merkely, Béla, Gorelik, Julia, Schneider, Michael D., Ali, Nadire N., Harding, Sian E. · 2011 · Journal of Molecular and Cellular Cardiology
Cited by 127

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Human embryonic stem cell-derived cardiomyocytes (hESC-CM) are being developed for tissue repair and as a model system for cardiac physiology and pathophysiology. However, the signaling requirements of their growth have not yet been fully characterized. We showed that hESC-CM retain their capacity for increase in size in long-term culture. Exposing hESC-CM to hypertrophic stimuli such as equiaxial cyclic stretch, angiotensin II, and phenylephrine (PE) increased cell size and volume, percentage of hESC-CM with organized sarcomeres, levels of ANF, and cytoskeletal assembly. PE effects on cell size were separable from those on cell cycle. Changes in cell size by PE were completely inhibited by p38-MAPK, calcineurin/FKBP, and mTOR blockers. p38-MAPK and calcineurin were also implicated in basal cell growth. Inhibitors of ERK, JNK, and CaMK II partially reduced PE effects; PKG or GSK3β inhibitors had no effect. The role of p38-MAPK was confirmed by an additional pharmacological inhibitor and adenoviral infection of hESC-CM with a dominant-inhibitory form of p38-MAPK. Infection of hESC-CM with constitutively active upstream MAP2K3b resulted in an increased cell size, sarcomere and cytoskeletal assembly, elongation of the cells, and induction of ANF mRNA levels. siRNA knockdown of p38-MAPK inhibited PE-induced effects on cell size. These results reveal an important role for active protein kinase signaling in hESC-CM growth and hypertrophy, with potential implications for hESC-CM as a novel in vitro test system. This article is part of a special issue entitled, "Cardiovascular Stem Cells Revisited".

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.yjmcc.2010.10.029

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 31

  1. Dolnikov, 2006, Functional properties of human embryonic stem cell-derived cardiomyocytes: intracellular Ca2+ handling and the role of sarcoplasmic reticulum in the contraction, Stem Cells, 24, 236, 10.1634/stemcells.2005-0036 · DOI · Paper page
  2. Synnergren, 2008, Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells, Stem Cells, 26, 1831, 10.1634/stemcells.2007-1033 · DOI
  3. Sartiani, 2007, Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach, Stem Cells, 25, 1136, 10.1634/stemcells.2006-0466 · DOI · Paper page
  4. Snir, 2003, Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes, Am J Physiol Heart Circ Physiol, 285, H2355, 10.1152/ajpheart.00020.2003 · DOI · Paper page
  5. Zhang, 2002, Stem cell-derived cardiomyocytes demonstrate arrhythmic potential, Circulation, 106, 1294, 10.1161/01.CIR.0000027585.05868.67 · DOI · Paper page
  6. Abdul Kadir, 2009, Embryonic stem cell-derived cardiomyocytes as a model to study fetal arrhythmia related to maternal disease, J Cell Mol Med, 13, 3730, 10.1111/j.1582-4934.2009.00741.x · DOI
  7. Xu, 2001, Feeder-free growth of undifferentiated human embryonic stem cells, Nat Biotechnol, 19, 971, 10.1038/nbt1001-971 · DOI · Paper page
  8. Laflamme, 2007, Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts, Nat Biotechnol, 25, 1015, 10.1038/nbt1327 · DOI · Paper page
  9. Gaub, 1975, Quantitative cytochemical aspects of a combined feulgen-naphthol yellow S staining procedure for the simultaneous determination of nuclear and cytoplasmic proteins and DNA in mammalian cells, Exp Cell Res, 92, 323, 10.1016/0014-4827(75)90386-9 · doi:10.1016/0014-4827(75)90386-9
  10. Novak, 2009, Nanoscale live-cell imaging using hopping probe ion conductance microscopy, Nat Meth, 6, 279, 10.1038/nmeth.1306 · doi:10.1038/nmeth.1306
  11. Korchev, 2000, Cell volume measurement using scanning ion conductance microscopy, Biophys J, 78, 451, 10.1016/S0006-3495(00)76607-0 · doi:10.1016/s0006-3495(00)76607-0
  12. Miyata, 2000, Myosin heavy chain isoform expression in the failing and nonfailing human heart, Circ Res, 86, 386, 10.1161/01.RES.86.4.386 · DOI · Paper page
  13. Shioi, 2003, Rapamycin attenuates load-induced cardiac hypertrophy in mice, Circulation, 107, 1664, 10.1161/01.CIR.0000057979.36322.88 · DOI · Paper page
  14. Boluyt, 2004, The mTOR/p70S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo, Cardiovasc Drugs Ther, 18, 257, 10.1023/B:CARD.0000041245.61136.56 · DOI
  15. Cao, 2008, Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes, PLoS ONE, 3, e3474, 10.1371/journal.pone.0003474 · DOI · Paper page
  16. Eble, 1998, Contractile activity is required for sarcomeric assembly in phenylephrine-induced cardiac myocyte hypertrophy, Am J Physiol, 274, C1226, 10.1152/ajpcell.1998.274.5.C1226 · doi:10.1152/ajpcell.1998.274.5.c1226
  17. Sugden, 2008, Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis, Br J Pharmacol, 153, S137, 10.1038/sj.bjp.0707659 · DOI · Paper page
  18. Klaiber, 2010, Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2, Basic Res Cardiol, 105, 583, 10.1007/s00395-010-0098-z · doi:10.1007/s00395-010-0098-z
  19. Aouadi, 2006, p38 mitogen-activated protein kinase activity commits embryonic stem cells to either neurogenesis or cardiomyogenesis, Stem Cells, 24, 1399, 10.1634/stemcells.2005-0398 · DOI
  20. Davidson, 2000, Hsp25 and the p38 MAPK pathway are involved in differentiation of cardiomyocytes, Dev Biol, 218, 146, 10.1006/dbio.1999.9596 · DOI
  21. Graichen, 2008, Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK, Differentiation, 76, 357, 10.1111/j.1432-0436.2007.00236.x · DOI · Paper page
  22. Androutsellis-Theotokis, 2006, Notch signalling regulates stem cell numbers in vitro and in vivo, Nature, 442, 823, 10.1038/nature04940 · DOI · Paper page
  23. Kyoi, 2006, Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster, Cardiovasc Res, 69, 888, 10.1016/j.cardiores.2005.11.015 · DOI
  24. Liu, 2005, Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction, J Card Fail, 11, 74, 10.1016/j.cardfail.2004.04.004 · DOI
  25. Behr, 2001, Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction, Circulation, 104, 1292, 10.1161/hc3601.094275 · DOI
  26. Petrich, 2004, Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies, Trends Cardiovasc Med, 14, 50, 10.1016/j.tcm.2003.11.002 · DOI
  27. McKinsey, 2007, Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface, Nat Rev Drug Discov, 6, 617, 10.1038/nrd2193 · DOI
  28. Heineke, 2006, Regulation of cardiac hypertrophy by intracellular signalling pathways, Nat Rev Mol Cell Biol, 7, 589, 10.1038/nrm1983 · DOI · Paper page
  29. Brill, 2009, Phosphoproteomic analysis of human embryonic stem cells, Cell Stem Cell, 5, 204, 10.1016/j.stem.2009.06.002 · DOI · Paper page
  30. Pawson, 2007, Dynamic control of signaling by modular adaptor proteins, Curr Opin Cell Biol, 19, 112, 10.1016/j.ceb.2007.02.013 · DOI · Paper page
  31. Arrell, 2010, Network systems biology for drug discovery, Clin Pharmacol Ther, 88, 120, 10.1038/clpt.2010.91 · DOI · Paper page

Cited by

See all 127

Metadata

Authors
Földes, G., Mioulane, M., Wright, J. S., Liu, A. Q., Novak, P., Merkely, B., Gorelik, J., Schneider, M. D., Ali, N. N., & Harding, S. E.
Venue
Journal of Molecular and Cellular Cardiology
Publisher
Elsevier BV
Published
2011-02
Volume
50
Issue
2
Pages
367-376
ISSN
0022-2828 (ISSN-L)
OpenAlex
W2084834807
Cited by
127
References
4
FWCI
3.54
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • BHF (OTKA F67919, MB08A 81237)
  • National Development Agency (TÁMOP 4.2.2-08/1/KMR-2008-0004)
  • NC3Rs
  • Rosetrees Trust

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modulation of human embryonic stem cell-derived cardiomyocyte growth: A testbed for studying human cardiac hypertrophy? https://app.cochat.ai/papers/10.1016/j.yjmcc.2010.10.029
The paper
Földes, G., Mioulane, M., Wright, J. S., Liu, A. Q., Novak, P., Merkely, B., Gorelik, J., Schneider, M. D., Ali, N. N., & Harding, S. E. (2011). Modulation of human embryonic stem cell-derived cardiomyocyte growth: A testbed for studying human cardiac hypertrophy? Journal of Molecular and Cellular Cardiology. https://doi.org/10.1016/j.yjmcc.2010.10.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.